Ratings by Oppenheimer (Mazahir Alimohamed)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/9/2026 | Edgewise Therapeutics | EWTX | New Coverage | Outperform (N/A) |
46.30 (39.76) |
-14.13% | Details | |
| 6/22/2026 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Outperform (Outperform) |
7.56 (8.56) |
13.23% | Details | |
| 6/17/2026 | Tyra Biosciences | TYRA | New Coverage | Outperform (N/A) |
28.21 (32.13) |
13.9% | Details | |
| 6/10/2026 | Inhibikase Therapeutics Inc | IKT | New Coverage | Outperform (N/A) |
1.67 (2.11) |
26.35% | Details | |
| 5/20/2026 | Tarsus Pharmaceuticals | TARS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2026 | Tarsus Pharmaceuticals | TARS | New Coverage | Outperform (N/A) |
60.97 (59.85) |
-1.84% | Details | |
| 4/24/2026 | Inflarx NV | IFRX | New Coverage | Outperform (N/A) |
1.56 (1.86) |
19.23% | Details | |
| 4/24/2026 | Savara | SVRA | New Coverage | Outperform (N/A) |
4.94 (5.52) |
11.74% | Details | |
| 4/24/2026 | Aquestive Therapeutics | AQST | New Coverage | Outperform (N/A) |
4.07 (4.12) |
1.23% | Details |
